Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).
MRI
PCNSL
PET
imaging
primary central nervous system lymphoma
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
pubmed:
10
2
2021
medline:
5
8
2021
entrez:
9
2
2021
Statut:
ppublish
Résumé
Advanced molecular and pathophysiologic characterization of primary central nervous system lymphoma (PCNSL) has revealed insights into promising targeted therapeutic approaches. Medical imaging plays a fundamental role in PCNSL diagnosis, staging, and response assessment. Institutional imaging variation and inconsistent clinical trial reporting diminishes the reliability and reproducibility of clinical response assessment. In this context, we aimed to: (1) critically review the use of advanced positron emission tomography (PET) and magnetic resonance imaging (MRI) in the setting of PCNSL; (2) provide results from an international survey of clinical sites describing the current practices for routine and advanced imaging, and (3) provide biologically based recommendations from the International PCNSL Collaborative Group (IPCG) on adaptation of standardized imaging practices. The IPCG provides PET and MRI consensus recommendations built upon previous recommendations for standardized brain tumor imaging protocols (BTIP) in primary and metastatic disease. A biologically integrated approach is provided to addresses the unique challenges associated with the imaging assessment of PCNSL. Detailed imaging parameters facilitate the adoption of these recommendations by researchers and clinicians. To enhance clinical feasibility, we have developed both "ideal" and "minimum standard" protocols at 3T and 1.5T MR systems that will facilitate widespread adoption.
Identifiants
pubmed: 33560416
pii: 6131740
doi: 10.1093/neuonc/noab020
pmc: PMC8248856
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1056-1071Subventions
Organisme : NCI NIH HHS
ID : U01 CA220378
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS082609
Pays : United States
Organisme : NCI NIH HHS
ID : L30 CA220897
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA239462
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA139083
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA221938
Pays : United States
Organisme : EPA
ID : EP-C-15-003
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA237809
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA158079
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA223757
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
Références
AJNR Am J Neuroradiol. 1996 Oct;17(9):1695-7
pubmed: 8896625
Neoplasia. 2009 Feb;11(2):102-25
pubmed: 19186405
Clin Cancer Res. 2012 Feb 15;18(4):1146-55
pubmed: 22228634
Neuro Oncol. 2017 Jan;19(1):118-127
pubmed: 27502247
Neuro Oncol. 2012 Jul;14(7):942-54
pubmed: 22711606
Neuro Oncol. 2008 Apr;10(2):223-8
pubmed: 18287338
Magn Reson Med Sci. 2019 Jan 10;18(1):53-61
pubmed: 29848919
Ann Oncol. 2017 Jul 1;28(7):1436-1447
pubmed: 28379322
J Clin Oncol. 2017 Jul 20;35(21):2410-2418
pubmed: 28640701
Leuk Lymphoma. 2019 Feb;60(2):515-518
pubmed: 30033836
AJNR Am J Neuroradiol. 2012 Jun;33(6):1081-7
pubmed: 22322605
Neuro Oncol. 2015 Sep;17(9):1188-98
pubmed: 26250565
J Nucl Med. 1992 Apr;33(4):532-6
pubmed: 1552337
J Neurooncol. 2011 Mar;102(1):163-6
pubmed: 20602148
Neuro Oncol. 2020 Jun 9;22(6):757-772
pubmed: 32048719
J Clin Oncol. 2005 Aug 1;23(22):5034-43
pubmed: 15955902
Eur J Radiol. 2016 Oct;85(10):1722-1727
pubmed: 27666608
Magn Reson Med. 1995 Oct;34(4):555-66
pubmed: 8524024
J Neurooncol. 2007 Sep;84(2):141-5
pubmed: 17406788
AJNR Am J Neuroradiol. 2013 Jan;34(1):35-40
pubmed: 22936096
CNS Oncol. 2021 Mar 1;10(1):CNS67
pubmed: 33322942
AJNR Am J Neuroradiol. 2015 Jun;36(6):E41-51
pubmed: 25907520
Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88
pubmed: 29117289
Eur J Nucl Med Mol Imaging. 2021 May 8;:
pubmed: 33966087
Neuroradiology. 1996 Jan;38(1):34-7
pubmed: 8773272
Radiology. 1999 Apr;211(1):257-63
pubmed: 10189481
AJNR Am J Neuroradiol. 2019 Apr;40(4):626-633
pubmed: 30923088
AJNR Am J Neuroradiol. 2010 Jan;31(1):60-6
pubmed: 19729544
Neuro Oncol. 2020 Sep 29;22(9):1262-1275
pubmed: 32516388
AJNR Am J Neuroradiol. 2016 Jan;37(1):74-9
pubmed: 26381553
Leuk Lymphoma. 2019 Sep;60(9):2278-2282
pubmed: 30628502
Radiology. 2009 Nov;253(2):486-96
pubmed: 19789240
AJNR Am J Neuroradiol. 2015 Dec;36(12):2242-9
pubmed: 26359151
Blood. 2018 Nov 22;132(21):2240-2248
pubmed: 30262659
AJNR Am J Neuroradiol. 2012 Jan;33(1):69-76
pubmed: 22095961
Ann Neurol. 1993 Mar;33(3):308-11
pubmed: 8498814
J Comput Assist Tomogr. 1999 Mar-Apr;23(2):232-7
pubmed: 10096330
AJNR Am J Neuroradiol. 2009 Mar;30(3):552-8
pubmed: 19056837
AJNR Am J Neuroradiol. 2006 Apr;27(4):859-67
pubmed: 16611779
Blood. 2019 Jul 18;134(3):252-262
pubmed: 31118164
Radiology. 2002 Jul;224(1):177-83
pubmed: 12091680
AJNR Am J Neuroradiol. 2010 May;31(5):868-73
pubmed: 20037130
Radiology. 2018 Jun;287(3):933-943
pubmed: 29361245
Eur J Radiol. 2019 Mar;112:59-64
pubmed: 30777220
Ann Nucl Med. 2011 Jul;25(6):432-8
pubmed: 21404136
AJNR Am J Neuroradiol. 2017 Mar;38(3):478-484
pubmed: 28034995
J Clin Neurosci. 2007 Nov;14(11):1126-9
pubmed: 17890092
Neuroimaging Clin N Am. 1999 May;9(2):343-61
pubmed: 10318719
J Magn Reson Imaging. 1999 Sep;10(3):223-32
pubmed: 10508281